Table 3.

Other secondary outcomes

	Placebo (95% CI)	Perampanel 4 mg (95% CI)	Perampanel 8 mg (95% CI)	Perampanel 4 mg vs. Placebo (95% CI)	p value	Perampanel 8 mg vs. Placebo (95% CI)	p value
Changes in ALSFRS-R score
At 4 weeks from baseline, n	− 1.3 (− 2.7 to –0.1), 22	− 1.3 (− 2.6 to − 0.0), 20	− 2.8 (− 4.2 to − 1.4), 21	− 0.0 (− 1.5 to 1.5)	0.9899	− 1.5 (− 3.0 to 0.0)	0.0526
At 12 weeks from baseline, n	− 1.9 (− 3.5 to − 0.4), 21	− 3.0 (− 4.5 to − 1.5), 18	− 5.2 (− 6.9 to − 3.5), 16	− 1.1 (− 3.0 to 0.8)	0.2495	− 3.3 (− 5.2 to − 1.4)	0.0012
At 24 weeks from baseline, n	− 5.0 (− 7.2 to − 2.8), 21	− 6.1 (− 8.5 to − 3.6), 15	− 7.4 (− 10.1 to − 4.7), 12	− 1.1 (− 4.2 to 2.1)	0.4953	− 2.4 (− 5.7 to 0.9)	0.1532
At 36 weeks from baseline, n	− 7.6 (− 10.8 to − 4.3), 19	− 9.6 (− 13.1 to − 6.0), 14	− 14.1 (− 18.1 to − 10.1), 10	− 2.0 (− 6.7 to 2.7)	0.3951	− 6.6 (− 11.6 to − 1.6)	0.0112
At 48 weeks from baseline, n	− 9.0 (− 13.1 to − 4.8), 18	− 13.4 (− 18.0 to − 8.8), 14	− 17.4 (− 22.7 to − 12.1), 7	− 4.5 (− 10.6 to 1.6)	0.1476	− 8.4 (− 15.0 to − 1.8)	0.0145
Total ALSFRS-R scorea
At 4 weeks	38.3 (36.3 to 40.3)	38.8 (36.9 to 40.7)	37.1 (35.1 to 39.1)	0.5 (− 1.7 to 2.7)	0.6722	− 1.3 (− 3.4 to 0.9)	0.2484
At 12 weeks	37.7 (35.7 to 39.7)	37.1 (35.1 to 39.0)	34.8 (32.6 to 36.9)	− 0.6 (− 2.9 to 1.7)	0.5813	− 2.9 (− 5.2 to − 0.6)	0.0142
At 24 weeks	34.6 (32.1 to 37.1)	34.0 (31.4 to 36.7)	32.7 (29.7 to 35.6)	− 0.6 (− 3.9 to 2.8)	0.7325	− 1.9 (− 5.4 to 1.5)	0.2665
At 36 weeks	32.1 (28.7 to 35.4)	30.9 (27.3 to 34.5)	26.3 (22.2 to 30.3)	− 1.2 (− 5.9 to 3.5)	0.6150	− 5.8 (− 10.8 to − 0.9)	0.0225
At 48 weeks	30.7 (26.6 to 34.8)	27.2 (22.8 to 31.7)	23.6 (18.4 to 28.9)	− 3.5 (− 9.3 to 2.4)	0.2351	− 7.1 (− 13.5 to − 0.7)	0.0315

ALS amyotrophic lateral sclerosis, ALSFRS-R ALS functional rating scale-revised

Analyses are based on date from the intention-to-treat population for all end points

^aNumbers of patients at each week are same as those in the changes in ALSFRS-R scores